NCT04163952View on ClinicalTrials.gov

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

February 21, 2025

Study Completion Date

February 21, 2025

Conditions
Locally Advanced Skin Squamous Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaRecurrent Skin Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Panitumumab

Given IV

BIOLOGICAL

Talimogene Laherparepvec

Given IM

Trial Locations (5)

10016

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

New York University Langone Medical Center, New York

NYU Langone Medical Center (Tisch Hospital), New York

27710

Duke University Medical Center - Duke Cancer Center, Durham

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER